Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Pharmaxis Ltd ( (AU:SNT) ) is now available.
Pharmaxis Ltd recently participated in the E&P 4th Annual Small Cap Healthcare Conference, where CEO Gary Phillips discussed the company’s strategic initiatives. The announcement highlighted the potential impact of Syntara’s product pipeline on Pharmaxis’s future financial position, emphasizing the inherent risks and uncertainties involved in product development and commercialization.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.06 price target. To see the full list of analyst forecasts on Pharmaxis Ltd stock, see the AU:SNT Stock Forecast page.
More about Pharmaxis Ltd
Average Trading Volume: 7,384,225
Technical Sentiment Signal: Sell
Current Market Cap: A$40.81M
For a thorough assessment of SNT stock, go to TipRanks’ Stock Analysis page.